# Benjamin Qiu

> Benjamin Qiu is a Series A investor at Advantech Capital backing Health Care. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Advantech Capital](https://shizune.co/investors/profile/advantech-capital)
- Location: Beijing, China
- Total investments: 6
- Last investment: Dec 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/benjamin-qiu-cfa-cma-4a20615/

Benjamin Qiu is a Series A investor at Advantech Capital in Beijing focused on Health Care and Pharmaceutical. Benjamin Qiu - Partner @ Advantech Capital

## Contacts

5 contacts available for Benjamin Qiu: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/benjamin-qiu?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 67% |
| Pharmaceutical | 4 | 67% |
| Biotechnology | 3 | 50% |
| Therapeutics | 2 | 33% |
| Medical | 1 | 17% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 67% |
| Series B | 2 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 3 | 50% |
| United States | 2 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Innoforce Pharmaceuticals | Innoforce is a biopharma manufacturing firm that facilitates the development and commercialization of innovative medicines. | $58.8M | Series A | Dec 06, 2021 |  |
| Ablaze Pharmaceuticals | Ablaze Pharma is a clinical stage bio-pharmaceutical company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients. | $75M | Series A | Nov 29, 2021 |  |
| Onconano Medicine | OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue.OncoNano Medicineis a UTSW spinoff company based in Dallas, Texas. | $50M | Series B | Jun 17, 2021 |  |
| Alphamab Oncology | Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment with multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipelinein oncology/ immunology, and they are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally. | $60M | Series B | May 28, 2019 |  |
| Alphamab Oncology | Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment with multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipelinein oncology/ immunology, and they are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally. | $100M | Series A | Nov 16, 2018 |  |
| KBP Biosciences | KBP is a world-class biotechnology research & development organization dedicated to providing innovative therapies for unmet medical needs. | $76M | Series A | Jan 05, 2018 |  |

6 of 6 investments shown.

## Co-investors
- [China Venture Capital](https://shizune.co/investors/profile/china-venture-capital) — VC Fund, 2 deals together
- [PAG](https://shizune.co/investors/profile/pag) — VC Fund, 2 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 1 deal together
- [CASH Capital](https://shizune.co/investors/profile/cash-capital) — VC Fund, 1 deal together
- China Highrun Capital Limited — VC Fund, 1 deal together
- [CICC](https://shizune.co/investors/profile/cicc) — VC Fund, 1 deal together

## About Advantech Capital

VC Fund · Central, Hong Kong

Advantech Capital is a private equity fund, focused on innovation-driven growth capital in China.

5 contacts available at Advantech Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Hebert Kee Chan Pang | Director | — |
| Jennifer Jin | Partner | — |
| Benjamin Qiu | Partner | — |
| Jianming Yu | Founder, Managing Partner | https://shizune.co/investors/profile/jianming-yu |
| Jianming Yu | Founder, Managing Partner | https://shizune.co/investors/profile/jianming-yu-4564 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Benjamin Qiu invest in?

Benjamin Qiu invests primarily in Health Care, Pharmaceutical and Biotechnology startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Benjamin Qiu?

Public channels for Benjamin Qiu include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Benjamin Qiu last invest?

The most recent investment recorded for Benjamin Qiu closed in Dec 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co